Search our Database of Scientific Publications and Authors

Iā€™m looking for a

    Details and Download Full Text PDF:
    Challenges in implementing model-based phase I designs in a grant-funded clinical trials unit.

    Trials 2017 Dec 28;18(1):620. Epub 2017 Dec 28.
    CRUK MRC Oxford Institute for Radiation Oncology, Gray Laboratories, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.
    Background: For a clinical trials unit to run its first model-based, phase I trial, the statistician, chief investigator, and trial manager must all acquire a new set of skills. These trials also require a different approach to funding and data collection.

    Challenges And Discussion: From the statisticians' viewpoint, we highlight what is needed to move from running rule-based, early-phase trials to running a model-based phase I study as we experienced it in our trials unit located in the United Kingdom. Our example is CHARIOT, a dose-finding trial using the time-to-event continual reassessment method. It consists of three stages and aims to discover the maximum tolerated dose of the combination of radiotherapy, chemotherapy, and the ataxia telangiectasia mutated Rad3-related inhibitor M6620 (previously known as VX-970) in patients with oesophageal cancer. We present the challenges we faced in designing this trial and how we overcame them as a way of demystifying the conduct of a model-based trial in a grant-funded clinical trials unit.

    Conclusions: Although we appreciate that undertaking model-based trials requires additional time and effort, they are feasible to implement and, once suitable tools such as guiding publications and document templates become available, the design and set-up process will be easier and more efficient.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with
    Source Status ListingPossible

    Similar Publications

    Implementation of a two-group likelihood time-to-event continual reassessment method using SAS.
    Comput Methods Programs Biomed 2015 Oct 16;121(3):189-96. Epub 2015 Jun 16.
    Department of Biostatistics, University of Alabama at Birmingham, School of Public Health, 1665 University Blvd., Room 327, Birmingham, AL 35294-0022, USA.
    Background And Objectives: Dose finding trials using model-based methods have the ability to handle the increasingly complex landscape being seen in clinical trials. Issues such as patient heterogeneity in trial populations are important to address in the designing of a trial in addition to the inclusion/exclusion criteria. Designs accommodating patient heterogeneity have been described using the continual reassessment method (CRM) and time-to-event CRM (TITE-CRM), yet, the implementation of these trials in practice have been limited. Read More
    A web tool for designing and conducting phase I trials using the continual reassessment method.
    BMC Cancer 2018 02 5;18(1):133. Epub 2018 Feb 5.
    Division of Translational Research & Applied Statistics, Department of Public Health Sciences, University of Virginia, P.O. Box 800717, Charlottesville, VA, USA.
    Background: Broad implementation of model-based dose-finding methods, such as the continual reassessment method (CRM), has been limited, with traditional or modified 3ā€‰+ā€‰3 designs remaining in frequent use. Part of the reason is the lack of reliable, easy-to-use, and robust software tools for designing and implementing more efficient designs.

    Results: With the aim of augmenting broader implementation of model-guided methods, we have developed a web application for the Bayesian CRM in the R programming language using the Shiny package. Read More
    Embracing model-based designs for dose-finding trials.
    Br J Cancer 2017 Jul 29;117(3):332-339. Epub 2017 Jun 29.
    Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
    Background: Dose-finding trials are essential to drug development as they establish recommended doses for later-phase testing. We aim to motivate wider use of model-based designs for dose finding, such as the continual reassessment method (CRM).

    Methods: We carried out a literature review of dose-finding designs and conducted a survey to identify perceived barriers to their implementation. Read More
    Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Clin Trials 2012 Jun 30;9(3):303-13. Epub 2012 Apr 30.
    Division of Cancer Biostatistics, Markey Cancer Center, University of Kentucky, Lexington, USA.
    Background: Various dose-finding clinical trial designs, including the continual reassessment method (CRM), dichotomize toxicity outcomes based on prespecified dose-limiting toxicity (DLT) criteria. This loss of toxicity information is particularly inefficient due to the small sample sizes in phase I trials, especially when Common Terminology Criteria for Adverse Events (CTCAE v4.0) are an established ordinal toxicity grading classification already used in the clinical practice. Read More